View Post

Uganda's Recent Ebola Outbreak Ends

In Travel Vaccine News by Travel Vaccine

There was very good news reported today by the World Health Organization (WHO) in Africa regarding the recent Sudan ebolavirus outbreak in the Republic of Uganda.
Today, the government of Uganda declared the end to the Ebola outbreak that began in September 2022, The last patient was released from care in late November 2022, which started the 42-day countdown to the end of the outbreak.
This was Uganda's first Sudan ebolavirus outbreak in a decade and its fifth overall for this kind of Ebola.

View Post

Uganda's 5th Sudan Ebola Outbreak Ends

In Travel Vaccine News by Travel Vaccine

There was very good news reported today by the World Health Organization (WHO) in Africa regarding the recent Sudan ebolavirus outbreak in the Republic of Uganda.
Today, the government of Uganda declared the end to the Ebola outbreak that began in September 2022, The last patient was released from care in late November 2022, which started the 42-day countdown to the end of the outbreak.
This was Uganda's first Sudan ebolavirus outbreak in a decade and its fifth overall for this kind of Ebola.

View Post

Ebola Outbreak Ends Without New Vaccines

In COVID-19, Latest News by Precision Vaccinations

The World Health Organization (WHO) in Uganda today announced great news regarding the recent Sudan ebolavirus outbreak.
The Republic of Uganda declared on January 11, 2023, the end of the Ebola disease outbreak less than four months after the initial patient was confirmed in the east African country's central Mubende district.
The last patient was released from care on November 30, 2022, when the 42-day countdown to the outbreak's end began. 
It was Uganda's first Sudan ebolavirus (SUDV) outbreak in a decade and its fifth overall for this kind of Ebola.

View Post

Bladder Cancer Treatment Innovates in the Right Direction

In COVID-19, Latest News by Precision Vaccinations

After 40 years, the Bacillus Calmette–Guérin (BCG) vaccine has remained the most effective treatment for non–muscle-invasive bladder cancer (NMIBC), wrote researchers with Memorial Sloan Kettering Cancer Center.
However, tumor recurrence and progression are common, especially for those patients with carcinoma in situ (CIS), commented Eugene J. Pietzak, M.D. and Harry W. Herr, M.D., in an Editorial published by the NEJM Evidence on December 27, 2022.
Furthermore, therapeutic options are limited when BCG treatment fails. 

View Post

Three-Dose Malaria Vaccine Candidate Shows Promise

In COVID-19, Latest News by Precision Vaccinations

A recent article published by the Infectious Disease Special Edition highlights the safety and efficacy demonstrated by Sanaria's non-replicating whole parasite PfSPZ malaria vaccine candidate.
The new study involved 80 participants in a randomized controlled clinical trial comparing three doses of the PfSPZ vaccine against a placebo.
Vaccine efficacy was shown to be 48% at six months (P=0.061) and 46% at 18 months (P=0.018).